Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of ChAdOx1 nCoV-19 Vaccine in Hemodialysis Patients vs Healthy Volunteers (Wild-Type and Delta Variants)
TCTR20211026002Recruiting
- Sponsor
- Kao Tun Roke Foundation
- Start
- Jun 2021
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kao Tun Roke Foundation. Primary endpoints: Immunogenicity against wild-type SARS-CoV-2 and Immunogenicity against Delta variant of SARS-CoV-2. Started Jun 2021; status: recruiting.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20211026002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211026002.